source
- Argenx to acquire Unnatural Products' macrocyclic peptide platform for $550 million upfrontArgenx announced that it will acquire the California-based protein specialist Unnatural Products, paying $550 million upfront for its macrocyclic peptide platform. The deal could rise to more than…
- Delix Therapeutics secures $100 million Series C to advance psychedelic pipelineDelix Therapeutics announced it has closed a $100 million Series C financing round. The capital will be used to accelerate development of its pipeline of psychedelic and neuroplastogen candidates…